Financial Performance - The group's revenue increased by 7.5% from RMB 3,022.4 million for the year ended December 31, 2024, to RMB 3,249.1 million for the year ended December 31, 2025[3]. - Gross profit rose by 11.3% from RMB 909.3 million in 2024 to RMB 1,012.4 million in 2025[3]. - EBITDA increased by 22.7% from RMB 506.9 million for the year ended December 31, 2024, to RMB 621.9 million for the year ended December 31, 2025[3]. - Net profit grew by 14.6% from RMB 307.2 million in 2024 to RMB 352.1 million in 2025[3]. - Basic earnings per share for the year ended December 31, 2025, was RMB 1.49, compared to RMB 1.26 in 2024[6]. - The company reported a total comprehensive income of RMB 338.3 million for the year ended December 31, 2025, compared to RMB 319.5 million in 2024[6]. - The company reported a pre-tax profit of RMB 680,012 thousand for 2025, up from RMB 543,115 thousand in 2024, marking a growth of 25.3%[29]. - Total tax expense for 2025 is RMB 71,577,000, an increase from RMB 56,101,000 in 2024, representing a growth of approximately 27.6%[37]. - Adjusted net profit rose by 0.55% from RMB 400.4 million for the year ending December 31, 2024, to RMB 402.6 million for the year ending December 31, 2025[89]. Assets and Liabilities - Total assets decreased from RMB 2,892.8 million in 2024 to RMB 2,840.4 million in 2025[8]. - Current liabilities increased significantly from RMB 763.3 million in 2024 to RMB 1,152.1 million in 2025[8]. - Non-current liabilities rose from RMB 516.5 million in 2024 to RMB 656.0 million in 2025[8]. - The company’s goodwill increased from RMB 1,132.5 million in 2024 to RMB 1,327.5 million in 2025[7]. - As of December 31, 2025, the total interest-bearing bank loans amounted to RMB 306.7 million, a significant increase from RMB 100.1 million as of December 31, 2024[92]. Revenue Breakdown - Revenue from healthcare solutions was RMB 3,219,648 thousand in 2025, up from RMB 2,987,656 thousand in 2024, reflecting an increase of 7.7%[24]. - Revenue from sales of healthcare products decreased to RMB 29,422 thousand in 2025 from RMB 34,721 thousand in 2024, a decline of 15.3%[24]. - Revenue from mainland China accounted for RMB 3,238,764 thousand in 2025, compared to RMB 3,019,225 thousand in 2024, representing a growth of 7.3%[19]. - Revenue from offline medical institutions increased by 8.8% to RMB 2,982.7 million for the year ended December 31, 2025, compared to RMB 2,740.5 million for the year ended December 31, 2024[72]. - Revenue from the online healthcare platform decreased by 5.5% to RMB 266.4 million for the year ended December 31, 2025, down from RMB 281.9 million for the year ended December 31, 2024[72]. Operational Developments - The company plans to continue expanding its online healthcare platform, which has been operational since 2018, enhancing patient access and resource allocation[46]. - The company aims to strategically select regions for offline expansion based on online physician and customer activity levels[46]. - The company has developed a combination of traditional Chinese medicine (TCM) and Western medicine treatment methods, launching the "Gu Shengtang TCM Education and Research Project" in collaboration with Nanyang Technological University in Singapore in 2025[47]. - The company launched the "National Medicine AI Avatar" in June 2025, with a total of 13 AI avatars covering 8 core TCM specialties, addressing the shortage of quality medical resources and improving patient treatment experiences[48]. - The company aims to leverage AI technology in medical scenarios, accelerating the development of industry models and smart healthcare solutions as part of the government's push for digital TCM development[53]. Customer Engagement and Membership - The company has established a comprehensive membership system, enhancing customer engagement and loyalty through a one-year membership card program[26]. - Membership numbers increased to 477,294 in 2025, with member visit counts rising to 2,354 thousand, demonstrating strong customer loyalty[60]. - The customer base grew steadily, with new customers increasing to 968,265 in 2025 from 889,070 in 2024, and total cumulative customers reaching 5,394,132[60]. - The number of patient visits increased to 6,008 thousand in 2025, up from 5,411 thousand in 2024, indicating a rise in service utilization[60]. - The customer retention rate was 66.1% in 2025, slightly down from 67.1% in 2024, while the average spending per visit decreased to RMB 541 from RMB 559[60]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance codes, except for the combined roles of Chairman and CEO held by Mr. Tu[108]. - The company is committed to reviewing and monitoring its corporate governance practices to ensure compliance with the governance code[109]. - The company established an audit committee to oversee compliance, accounting policies, and financial reporting procedures[118]. - The independent auditor has reviewed the preliminary financial results for the year ending December 31, 2025[119]. Future Plans and Investments - The company plans to enhance its OMO platform and brand value while integrating AI into traditional Chinese medicine to improve service quality and resource allocation[63]. - The company is increasing R&D investments to standardize and productize healthcare solutions, with several traditional Chinese medicine formulations receiving regulatory approval for production[65]. - The company is advancing its international strategy by acquiring 100% of Dazhongtang and expanding its presence in Singapore, with three products already certified by the Singapore Health Sciences Authority[66]. - The company is actively developing light clinics to cater to both consumer-grade and medical-grade services, leveraging the significant market potential in China's healthcare sector[66]. - The company aims to enrich its product portfolio with 10% of the placement proceeds (approximately HKD 54 million) allocated for this initiative[106].
固生堂(02273) - 2025 - 年度业绩